| 1. Executive Summary |
| 2. Global MRNA Therapeutics Market Introduction |
| 2.1. Global MRNA Therapeutics Market – Taxonomy |
| 2.2. Global MRNA Therapeutics Market –Definitions |
| 2.2.1. By Type |
| 2.2.2. By Application |
| 2.2.3. By End User |
| 2.2.4. By Region |
| 3. Global MRNA Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Pipeline Analysis |
| 3.6. Market Product Analysis |
| 3.7. Disease Landscape |
| 3.8. Product Landscape |
| 3.9. Global MRNA Therapeutics Market Dynamic Factors – Impact Analysis |
| 3.10. Global MRNA Therapeutics Market – Competition Landscape |
| 4. Global MRNA Therapeutics Market Analysis,2017-2021 and Forecast, 2022-2028 |
| 4.1. Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global MRNA Therapeutics Market, By Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1. Prophylactic Vaccines |
| 5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Therapeutic Vaccines |
| 5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Therapeutic Drugs |
| 5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global MRNA Therapeutics Market Forecast, By Application, 2017-2021 and Forecast, 2021 – 2027 (Revenue, USD Mn) |
| 6.1. Rare Genetic Diseases |
| 6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Oncology |
| 6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Respiratory Diseases |
| 6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Infectious Diseases |
| 6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global MRNA Therapeutics Market, By End User, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1. Hospitals & Clinics |
| 7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Research Organizations |
| 7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global MRNA Therapeutics Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global MRNA Therapeutics Market – Opportunity Analysis Index, By Type, Application, End User, and Region, 2022-2028 |
| 9. North America MRNA Therapeutics MarketAnalysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.1. By Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Prophylactic Vaccines |
| 9.1.2. Therapeutic Vaccines |
| 9.1.3. Therapeutic Drugs |
| 9.2. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Rare Genetic Diseases |
| 9.2.2. Oncology |
| 9.2.3. Respiratory Diseases |
| 9.2.4. Infectious Diseases |
| 9.2.5. Others |
| 9.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Hospitals & Clinics |
| 9.3.2. Research Organizations |
| 9.3.3. Others |
| 9.4. Country Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America MRNA Therapeutics Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022-2028 |
| 9.6. North America MRNA Therapeutics Market Dynamics – Trends |
| 10. Europe MRNA Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.1. By Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Prophylactic Vaccines |
| 10.1.2. Therapeutic Vaccines |
| 10.1.3. Therapeutic Drugs |
| 10.2. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Rare Genetic Diseases |
| 10.2.2. Oncology |
| 10.2.3. Respiratory Diseases |
| 10.2.4. Infectious Diseases |
| 10.2.5. Others |
| 10.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Hospitals & Clinics |
| 10.3.2. Research Organizations |
| 10.3.3. Others |
| 10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Rest of Europe |
| 10.5. Europe MRNA Therapeutics Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022-2028 |
| 10.6. Europe MRNA Therapeutics Market Dynamics – Trends |
| 11. Asia-Pacific MRNA Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 11.1. By Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Prophylactic Vaccines |
| 11.1.2. Therapeutic Vaccines |
| 11.1.3. Therapeutic Drugs |
| 11.2. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Rare Genetic Diseases |
| 11.2.2. Oncology |
| 11.2.3. Respiratory Diseases |
| 11.2.4. Infectious Diseases |
| 11.2.5. Others |
| 11.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Hospitals & Clinics |
| 11.3.2. Research Organizations |
| 11.3.3. Others |
| 11.4. Country Analysis2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific MRNA Therapeutics Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022-2028 |
| 11.6. Asia-Pacific MRNA Therapeutics Market Dynamics – Trends |
| 12. Latin America MRNA Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 12.1. By Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Prophylactic Vaccines |
| 12.1.2. Therapeutic Vaccines |
| 12.1.3. Therapeutic Drugs |
| 12.2. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Rare Genetic Diseases |
| 12.2.2. Oncology |
| 12.2.3. Respiratory Diseases |
| 12.2.4. Infectious Diseases |
| 12.2.5. Others |
| 12.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Hospitals & Clinics |
| 12.3.2. Research Organizations |
| 12.3.3. Others |
| 12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America MRNA Therapeutics Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022-2028 |
| 12.6. Latin America MRNA Therapeutics Market Dynamics – Trends |
| 13. Middle East and Africa MRNA Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 13.1. By Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Prophylactic Vaccines |
| 13.1.2. Therapeutic Vaccines |
| 13.1.3. Therapeutic Drugs |
| 13.2. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Rare Genetic Diseases |
| 13.2.2. Oncology |
| 13.2.3. Respiratory Diseases |
| 13.2.4. Infectious Diseases |
| 13.2.5. Others |
| 13.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Hospitals & Clinics |
| 13.3.2. Research Organizations |
| 13.3.3. Others |
| 13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA MRNA Therapeutics Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022-2028 |
| 13.6. MEA MRNA Therapeutics Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Application& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Moderna, Inc. |
| 14.2.2. BioNTech SE |
| 14.2.3. CureVac N.V. |
| 14.2.4. Arcturus Therapeutics |
| 14.2.5. Translate Bio, Inc. |
| 14.2.6. GSK plc. |
| 14.2.7. Argos Therapeutics Inc. |
| 14.2.8. Sangamo Therapeutics, Inc. |
| 14.2.9. Pfizer Inc. |
| 14.2.10. AstraZeneca plc. |
| 14.2.11. Sanofi |
| 14.2.12. CRISPR Therapeutics AG |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
Request Sample
Request Methodology
